Salmeterol xinafoate

Research use only, not for human use.

A long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD.

A long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD. Asthma Approved(In Vitro):Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation.(In Vivo):Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD).

Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation. Cell Proliferation Assay Cell Line:Human T lymphocytes (THP-1 cells) Concentration:0.001, 0.01, 0.05, 0.2, 1, 5, and 25 μM Incubation Time:Result:The proliferation of Th2 cells was inhibited in a concentration dependent manner.

Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD). Animal Model:Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g)Dosage:Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg) Administration:The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period. Result:COPD assessment test scores were markedly improved in mice with COPD.

GR-33343X xinafoate

GPCR/G Protein

Adrenergic Receptor

WTβ2AR

Inflammation/Immunology

Asthma

94749-08-3

603.745

C36H45NO7

>98% (HPLC)

DMSO: ≥ 50 mg/mL

C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O

2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1)

(-20℃)

With Ice Pack

≥ 2 years